Previous Close | 3.88 |
1-Year Change | 65.11% |
6-Months Change | -47.78% |
3-Months Change | 8.08% |
Moving Avg (50d) | 4.0198 |
Moving Avg (200d) | 4.6633 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 382.5M |
Beta (3-Years) | 1.97 |
Revenue Growth (ttm) | 53.9% |
Net Profit Margin (ttm) | -163.04% |
Return On Assets (ttm) | -31.84% |
EPS (ttm) | -1.77 |
PE Ratio (ttm) | -2.19 |
Dividend Yield | % |
Asset Description: | Fate Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
3.802 | 3.686 | 3.608 | 3.492 | 3.298 | 3.104 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |